Navigation Links
Anemia may Lead to Physical Decline

A new study shows anemia may double the risk of an older person developing serious physical declines that can erode the ability to live independently. Researchers say seniors who do not have anemia, but whose blood tests are just above the traditional cut-off point for the condition's diagnosis, are 1.5-times more likely to develop physical declines than those who have normal blood hemoglobin levels.//

Investigators followed 1,146 people, ages 71 and older, for more than four years. Researchers assessed participants' standing balance, a timed eight-foot walk, and the ability to rise from a chair. Each activity was scored on a scale (a zero equaled inability to do a test; a four equaled a top performance). Points were then added together for a cumulative score.

Results of the study show two-thirds of participants had at least modest declines in physical performance scores. Those who did not have anemia averaged a 1.4-point decline on the overall 12-point scale. Those who had borderline anemia dipped an average of 1.8 points and those with anemia dropped an average of 2.3 points.

Anemia is a blood condition that affects at least 3.4 million Americans and about 13 percent of older Americans. It is the most common blood disorder in the United States. The condition occurs when the body doesn't produce enough red blood cells or red blood cells are prematurely destroyed.
'"/>




Page: 1

Related medicine news :

1. Anemia Treatment for Cancer Patients
2. Anemia Treatment for Cancer Patients
3. Anemia Treatment for Cancer Patients Might Not be a Good Idea.
4. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
5. Treatment of Sickle Cell Anemia Using Gene Therapy.
6. Treating Sickle Cell Anemia using Healthy Stem Cells
7. Anemia from Malaria Linked to a Protein MIF
8. EPO Effective For Cancer Patients Suffering From Anemia
9. Amgen introduces Autoinjector For Treating Anemia
10. Anemia Affects Both Body and Mind
11. Exercise alleviates Anemia in Breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... Virginia (PRWEB) , ... December 08, 2016 , ... ... services company offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care ... operations and general counsel and Eric Hoessel to vice president of sales. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... 2016 Mitsubishi Tanabe Pharma Corporation (Head Office: ... CEO: Dr. Masayuki Mitsuka ) has presented data ... edaravone intravenously in 10-14 day cycles for 48 weeks ... ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented ... in Dublin, Ireland . ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
Breaking Medicine Technology: